General

Cell Line
hPSCreg name	CBIGi007-A-1
Cite as: When citing this cell line, please use the hPSCreg name (see Naming Tool ) and the corresponding Research Resource ID (RRID).	CBIGi007-A-1
Alternative name(s)	IPSC0009, TMEM175 Q65Q homozygous correction
Cell line type	Human induced pluripotent stem cell (hiPSC)
Similar lines	No similar lines found.
Last update	24th March 2025
Notes	Isogenic control for CBIGi007-A.
User feedback show/hide	Written by on Delete No feedback available yet. Login to share your feedback, experiences or results with the research community.
Provider
Generator	Clinical Biospecimen Imaging and Genetic (C-BIG) Repository (CBIG) Contact: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository (CBIG)
Distributors	Clinical Biospecimen Imaging and Genetic (C-BIG) Repository (CBIG)
Derivation country	Canada
External Databases
BioSamples	SAMEA117843740
General Information
* Is the cell line readily obtainable for third parties?	Yes Research use: allowed Clinical use: not allowed Commercial use: not allowed
Subclone of	CBIGi007-A

Donor Information

General Donor Information
Sex	female
Phenotype and Disease related information (Donor)
Diseases	A disease was diagnosed. Parkinson Disease Synonyms Parkinson Disease Parkinson's disease Parkinson's Disease Genetic variants TMEM175 (target) Chromosome location 4p16.3 Nucleotide sequence variant in HGVS format NM_032326.48.3: c.194 A>C Protein sequence variant in HGVS format NP_115702.1: p.Gln65 Pro (Q65P) Is the variant homozygous or heterozygous? Heterozygous
External Databases (Donor)
BioSamples	SAMEA117843389

Ethics

Also have a look at the ethics information for the parental line CBIGi007-A .

For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General
The source cell information can be found in the parental cell line CBIGi007-A.
Passage number reprogrammed	P16
Reprogramming method
Vector type	Non-integrating
Vector	Episomal
Is reprogramming vector detectable?	Unknown
Vector free reprogramming
Other
Derived under xeno-free conditions	Unknown
Derived under GMP?	Unknown
Available as clinical grade?	Unknown

Culture Conditions

Surface coating	Matrigel/Geltrex
Passage method	Enzyme-free cell dissociation Gentle Cell Dissociation Reagent
O2 Concentration	21 %
CO2 Concentration	5 %
Medium	mTeSR™ 1 EDDU-002-002_iPSC_Culture_cPDF_v2_0.pdf
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?	Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?	No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?	Yes

Characterisation

Analysis of Undifferentiated Cells

Marker Expression

Marker	Expressed	Immunostaining	RT-PCR	Flow Cytometry	Enzymatic Assay	Expression Profiles
NANOG	Yes
TRA 1-60	Yes
SSEA-4	Yes
POU5F1 (OCT-4)	Yes

Microbiology / Virus Screening
HIV 1	Negative
HIV 2	Negative
Hepatitis B	Negative
Hepatitis C	Negative
Mycoplasma	Negative

Genotyping

Karyotyping (Cell Line)
Has the cell line karyotype been analysed?	Yes Normal, 46 XX Passage number: P16 Karyotyping method: G-Banding
Other Genotyping (Cell Line)

Genetic Modification

Genetic modifications not related to a disease

TMEM175 (target) Type of modification Isogenic modification Chromosome location 4p16.3 Is the modification homozygous or heterozygous? Heterozygous Free text After CRISP/Cas9 editing, DNA Sanger sequence confirms that the wt codon CAG (Gln, Q) has replace the mutant CMG (Pro, P), correcting the missense mutation Q65P. *Note that three silent mutations were introduced in the corrected allele (heterozygous) around the target codon. How has the target locus been modified? Repaired